In a report released today, Yigal Nochomovitz from Citigroup maintained a Hold rating on Merus NV (MRUS), with a price target of $16. The company’s shares closed yesterday at $13.13, close to its 52-week low of $11.
According to TipRanks.com, Nochomovitz is a 4-star analyst with an average return of 9.3% and a 50.7% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Crispr Therapeutics AG, and Aldeyra Therapeutics.
Merus NV has an analyst consensus of Moderate Buy, with a price target consensus of $25.
Based on Merus NV’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $12.43 million. In comparison, last year the company had a GAAP net loss of $16.77 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.